Trends in Cardiovascular Medicine
Volume 15, Issue 8 , Pages 278-282 , November 2005

Nicotinamide Adenine Dinucleotide Phosphate Oxidase: A Promiscuous Therapeutic Target for Cardiovascular Drugs?

  • Saima Muzaffar
    • ,
  • Nilima Shukla
    • ,
  • Jamie Y. Jeremy

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Jamie Y. Jeremy, Department of Cardiac Surgery, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, BS2 8HW Bristol, UK. Tel.: (+44) 0117-928-2699.

References 

  1. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218
  2. Barbior B. Phagocytes and oxidative stress. Am J Med. 2000;109:33–44
  3. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107–1111
  4. Bleeke T, Zhang H, Madamanchi N, et al. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94:37–45
  5. Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med. 2003;7:11–20
  6. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471–478
  7. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci. 2003;73:1813–1824
  8. Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: Role of ET(B) receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323–333
  9. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1114–1148
  10. Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  11. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237–268
  12. Guzik TZ, West NEJ, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85–E90
  13. Hayashi T, Juliet PA, Kano-Hayashi H, et al. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes Metab. 2005;7:334–343
  14. Isner JM. Vascular endothelial growth factor: Gene therapy and therapeutic angiogenesis. Am J Cardiol. 1998;82:63S–64S
  15. Jacobson GM, Dourron HM, Liu J, et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003;92:637–643
  16. Jeremy JY, Mikhalidis D, Dandona P. Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis. Eur J Pharmacol. 1985;107:259–262
  17. Jeremy JY, Mehta D, Bryan AJ, Angelini GD. Platelets and saphenous vein graft failure. Platelets. 1997;8:295–309
  18. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res. 1999;43:658–665
  19. Jeremy JY, Yim AP, Wan S, Angelini GD. Oxidative stress, nitric oxide and vascular disease. Cardiovasc Surg. 2002;17:324–327
  20. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in endothelial and vascular wall. Endothelium. 2004;111:79–88
  21. Jung O, Schreiber JG, Geiger H, et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation. 2004;109:1795–1801
  22. Kamal AM, Flower RJ, Perretti M. An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz. 2005;100(Suppl 1):39–47
  23. Kouparris A, Jeremy JY, Muzaffar S, et al. Sildenafil inhibits the formation of superoxide and the expression of gp47phox NADPH oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. Br J Urol. 2005;96:423–427
  24. Krex D, Ziegler A, Konig IR, et al. Polymorphisms of the NADPH oxidase P22PHOX gene in a Caucasian population with intracranial aneurysms. Cerebrovasc Dis. 2003;16:363–368
  25. Li JM, Shah AM. Endothelial cell superoxide generation: Regulation and relevance for cardiovascular pathophysiology. Am J Physiol. 2004;287:R1014–R1030
  26. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053–1058
  27. Liu JQ, Zelko IN, Folz RJ. Reoxygenation-induced constriction in murine coronary arteries: The role of endothelial NADPH oxidase and intracellular superoxide. J Biol Chem. 2004;279:24493–24497
  28. Marumo T, Schini-Kerth VB, Brandes RP, et al. Glucocorticoids inhibit superoxide anion production and p22phox mRNA expression in human aortic smooth muscle cells. Hypertension. 1998;32:1083–1088
  29. McNally JS, Davis ME, Giddens DP, Saha A. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol. 2003;285:H2290–H2297
  30. Morrow JD, Roberts LJ. The isoprostanes: Their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med. 2002;166:S25–S30
  31. Mueller T, Dieplinger B, Gegenhuber A, et al. Serum total 8-iso-prostaglandin F2α a new and independent predictor of peripheral arterial disease. J Vasc Surg. 2004;40:768–773
  32. Muzaffar S, Jeremy JY, Angelini GD, et al. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax. 2003;58:598–604
  33. Muzaffar S, Shukla N, Lobo C, et al. Iloprost inhibits NADPH oxidase expression and superoxide release in porcine pulmonary arteries and cells stimulated with thromboxane A2, isoprostane F2α and cytokines. Br J Pharmacol. 2004;141:488–496
  34. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Nitroaspirins and morpholino-sydnonimine, but not aspirin, inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells. Circulation. 2004;110:1140–1147
  35. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Sildenafil citrate and NO-donating sildenafil, NCX 911, inhibit superoxide formation and gp91phox expression in pulmonary artery endothelial cells. Br J Pharmacol. 2005;146:109–117
  36. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Prednisolone augments superoxide formation in porcine pulmonary artery endothelial cells through upregulation of NADPH oxidase. Br J Pharmacol. 2005;145:688–697
  37. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the pulmonary artery. Thorax. 2005;60:305–313
  38. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide augments superoxide formation through upregulation of NADPH oxidase expression. (abstr) Br J Pharmacol. 2005;www.pa2online.org/Vol2Issue4abst017P.html
  39. Rey FE, Li XC, Carratero OA, et al. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: Role of gp91(phox). Circulation. 2002;106:2497–2502
  40. Shukla N, Angelini GD, Wan I, et al. Potential role of nitroaspirins in the treatment of vein graft failure. Ann Thorac Surg. 2003;75:1437–1442
  41. Shukla N, Koupparis A, Persad R, et al. Inhibitory effect of hyperhomocysteinaemia on relaxation of the aorta of the rabbit is reversed with penicillamine. Br J Pharmacol. 2005;www.pa2online.org/Vol2Issue4abst129P.html
  42. Shukla N, Jones R, Persad R, et al. Hypercholesterolaemia and erectile dysfunction: Role of superoxide generating enzymes and effect of a NO donating sildenafil derivative, NCX 911. Eur J Pharmacol. 2005;517:224–231
  43. Ullrich V, Zou MH, Bachsmid M. New physiological and pathophysiological aspects on the thromboxane A(2)-prostacyclin regulatory system. Biochim Biophys Acta. 2001;1532:1–14
  44. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160–1167
  45. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov. 2002;1:375–382
  46. Zhang H, Schmeiber A, Garlichs CD, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res. 1999;44:215–222

PII: S1050-1738(05)00155-6

doi: 10.1016/j.tcm.2005.09.001

Trends in Cardiovascular Medicine
Volume 15, Issue 8 , Pages 278-282 , November 2005

Article Tools

* Image Usage & Resolution